Beyondspring Ord (NASDAQ:BYSI) Stock Is Shorted More

September 17, 2017 - By Maria Brooks

 Beyondspring Ord (NASDAQ:BYSI) Stock Is Shorted More

The stock of Beyondspring Ord (NASDAQ:BYSI) registered an increase of 4.93% in short interest. BYSI’s total short interest was 44,700 shares in September as published by FINRA. Its up 4.93% from 42,600 shares, reported previously. With 4,700 shares average volume, it will take short sellers 10 days to cover their BYSI’s short positions.

The stock decreased 2.56% or $1 on September 15, reaching $38. About 2,545 shares traded. Beyondspring Inc (NASDAQ:BYSI) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The company has market cap of $868.11 million. The Firm is focused on the development of cancer therapies. It currently has negative earnings. The Firm is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer .

More notable recent Beyondspring Inc (NASDAQ:BYSI) news were published by: which released: “Maxim Group Starts BeyondSpring Inc. (BYSI) at Buy; Plinabulin Market …” on August 22, 2017, also with their article: “BeyondSpring Inc. to Present at Biotech Showcase 2017 During Annual JPMorgan …” published on January 10, 2017, published: “BeyondSpring Looks to Future After IPO/PIPE Launch” on September 16, 2017. More interesting news about Beyondspring Inc (NASDAQ:BYSI) were released by: and their article: “BeyondSpring Inc. Prices Initial Public Offering and Concurrent Private …” published on March 09, 2017 as well as‘s news article titled: “BeyondSpring Finds A Vascular-Disrupting Niche” with publication date: March 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.